Bispecific T-cell engager antibody that binds CD19 on B cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect endogenous T cells to kill CD19-positive malignant B cells.
Bispecific antibody that simultaneously binds CD19 on B cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect endogenous T cells to kill CD19-positive malignant B cells; includes an albumin-binding domain to extend half-life.
YES
DIRECT
Bispecific antibody bridges CD19 on target cells to CD3 on T cells, forming an immune synapse that activates T cells to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity.
Anti-HER2 antibody–drug conjugate that binds HER2, is internalized, and releases MMAE to inhibit microtubules, causing cell-cycle arrest/apoptosis and potential ADCC.
Anti-HER2 antibody-drug conjugate that binds HER2 on tumor cells, is internalized, and releases MMAE to inhibit tubulin polymerization, leading to G2/M cell-cycle arrest and apoptosis; may also mediate Fc-dependent ADCC.
YES
DIRECT
Binds HER2 on tumor cells, is internalized, and releases MMAE to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; Fc-mediated ADCC may also contribute.
An antibody–drug conjugate (ADC) consisting of a humanized anti–B7‑H3 (CD276) IgG1 linked via a protease‑cleavable linker to a duocarmycin DNA‑alkylating payload. After binding B7‑H3 on tumor cells and internalization, it releases the payload to cause DNA minor‑groove alkylation, DNA damage, and tumor cell death. Administered IV (2.7 mg/kg q28d).
Humanized anti-B7-H3 (CD276) IgG1 ADC with a protease-cleavable linker to a duocarmycin payload; after B7-H3 binding and internalization by tumor cells, linker cleavage releases duocarmycin, which binds the DNA minor groove and alkylates adenine (N3), causing DNA damage and tumor cell death.
NO
INDIRECT
MGC018 targets B7-H3 on tumor cells; after internalization, the duocarmycin payload is released and alkylates adenine N3 in the DNA minor groove, causing DNA damage and death. The DNA minor groove is the payload’s intracellular binding site, not the selective antigen used for targeting.
Bispecific T-cell engager antibody that binds CD19 on B cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect endogenous T cells to kill CD19-positive malignant B cells.
Bispecific antibody that simultaneously binds CD19 on B cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect endogenous T cells to kill CD19-positive malignant B cells; includes an albumin-binding domain to extend half-life.
NO
INDIRECT
CD3 binding activates and redirects T cells to kill CD19-positive B cells via immune-synapse formation and perforin/granzyme release; CD3+ T cells themselves are not targeted for killing.
Bispecific T-cell engager antibody that binds CD19 on B cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect endogenous T cells to kill CD19-positive malignant B cells.
Bispecific antibody that simultaneously binds CD19 on B cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect endogenous T cells to kill CD19-positive malignant B cells; includes an albumin-binding domain to extend half-life.
NO
INDIRECT
The HSA-binding domain serves to extend serum half-life and does not trigger T-cell engagement or killing; CLN-978 mediates cytotoxicity only by bridging CD19 on B cells with CD3 on T cells, leading to T cell–mediated lysis of CD19+ cells, not HSA-expressing cells.